Literature DB >> 26711696

Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis.

Cybele Ghossein1, John Varga2,3, Andrew Z Fenves4.   

Abstract

Scleroderma renal crisis (SRC) is an uncommon complication of systemic sclerosis. Despite the advent of angiotensin-converting inhibitor therapy, SRC remains a life-threatening complication. Recent studies have contributed to a better understanding of SRC, but much remains unknown regarding its pathophysiology, risk factors, and optimal management. Genetic studies provide evidence that immune dysregulation might be a contributing factor, providing hope that further research in this direction might illuminate pathogenesis and provide novel predictors for this complication.

Entities:  

Keywords:  Angiotensin-converting enzyme inhibitor (ACEI); Diffuse cutaneous disease (dcSSc); Immune dysregulation; Malignant hypertension; Renal biopsy; Scleroderma renal crisis (SRC); Systemic sclerosis; Thrombotic microangiopathy

Mesh:

Substances:

Year:  2016        PMID: 26711696     DOI: 10.1007/s11926-015-0551-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  34 in total

1.  Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.

Authors:  J A Lopez-Ovejero; S D Saal; W A D'Angelo; J S Cheigh; K H Stenzel; J H Laragh
Journal:  N Engl J Med       Date:  1979-06-21       Impact factor: 91.245

2.  Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Authors:  Amr Amin; S El-Sayed; N Taher; M Sedki; H Nasr
Journal:  Clin Rheumatol       Date:  2012-02-24       Impact factor: 2.980

3.  Successful medical treatment of scleroderma renal crisis.

Authors:  C Wasner; C R Cooke; J F Fries
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

4.  Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease.

Authors:  Sankalp Virendrakumar Bhavsar; Raj Carmona
Journal:  J Clin Rheumatol       Date:  2014-10       Impact factor: 3.517

Review 5.  Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature.

Authors:  Kristin M Logee; Santhanam Lakshminarayanan
Journal:  Clin Exp Rheumatol       Date:  2015-03-06       Impact factor: 4.473

6.  Long-term outcomes of scleroderma renal crisis.

Authors:  V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

Review 7.  Diagnosis, management and prevention of scleroderma renal disease.

Authors:  Henry Penn; Christopher P Denton
Journal:  Curr Opin Rheumatol       Date:  2008-11       Impact factor: 5.006

Review 8.  Scleroderma--clinical and pathological advances.

Authors:  Christopher P Denton; Carol M Black
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

9.  Scleroderma renal crisis: patient characteristics and long-term outcomes.

Authors:  H Penn; A J Howie; E J Kingdon; C C Bunn; R J Stratton; C M Black; A Burns; C P Denton
Journal:  QJM       Date:  2007-06-29

10.  Differentiating scleroderma renal crisis from other causes of thrombotic microangiopathy in a postpartum patient.

Authors:  Muaz Abudiab; Megan L Krause; Mary E Fidler; Karl A Nath; Suzanne M Norby
Journal:  Clin Nephrol       Date:  2013-10       Impact factor: 0.975

View more
  6 in total

Review 1.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

Review 2.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

3.  Renal pathology and clinical associations in systemic sclerosis: a historical cohort study.

Authors:  Pantipa Tonsawan; Komkid Talabthong; Anucha Puapairoj; Chingching Foocharoen
Journal:  Int J Gen Med       Date:  2019-09-02

4.  Patterns of renal pathology in Chinese patients with systemic sclerosis undergoing renal biopsy at a tertiary medical center.

Authors:  Xiao-Yu Cao; He Liu; Dong Xu; Meng-Tao Li; Qian Wang; Li Jiang; Yong Hou; Li-Xiu Zhu; Xiao-Feng Zeng
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

5.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

Review 6.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.